Breeze Holdings Acquisition, YD Biopharma enter definitive merger agreement
Merger Announcement: Breeze Holdings Acquisition has agreed to merge with YD Biopharma, a clinical-stage biopharmaceutical company focused on cancer diagnostics and exosome-based therapeutics, aiming for Nasdaq listing post-merger.
Expansion Plans: YD Biopharma plans to utilize the merger proceeds to enhance production and develop new technologies, including advanced detection methods for pancreatic and breast cancers, while continuing under the leadership of Dr. Ethan Shen.
Trade with 70% Backtested Accuracy
Analyst Views on BREZ
No data
About BREZ
About the author
Breeze Acquisition Corp. II Prices IPO at $10 per Unit
- IPO Pricing Announcement: Breeze Acquisition Corp. II has priced its initial public offering of 12,500,000 units at $10.00 per unit, with trading expected to commence on May 13, 2026, indicating strong market confidence in its future business combinations.
- Unit Composition and Trading: Each unit consists of one ordinary share and one right, with rights allowing holders to receive one-fifth of an ordinary share upon the completion of a business combination, designed to attract investors and enhance market appeal.
- Underwriters and Over-Allotment: IB Capital LLC and I-Bankers Securities, Inc. are acting as book-running managers, with underwriters granted a 45-day option to purchase up to 1,875,000 additional units, reflecting strong demand for the offering.
- Use of Proceeds and Strategic Focus: The net proceeds from the offering will be utilized to fund business combinations with companies having global operations and differentiated technologies, particularly in healthcare, biotechnology, and artificial intelligence, highlighting the company's focus on high-growth sectors.
Breeze Holdings Acquisition Corp. Shareholders Approve Business Combination with YD Biopharma Limited
Business Combination Approval: Breeze Holdings Acquisition Corp. has received stockholder approval for its business combination with YD Biopharma Limited, a Taiwan-based biopharmaceutical company, and the new entity will be named YD Bio Limited, expected to trade on Nasdaq under the ticker symbol "YDES."
Company Focus and Future Plans: YD Biopharma is dedicated to developing innovative vaccines and therapeutics for infectious diseases and aims to transform treatment options for various high unmet medical needs, with the transaction expected to close within two weeks.
Breeze Holdings Acquisition Corp. Announces Definitive Agreement to Merge with YD Biopharma Limited
Proposed Merger: YD Biopharma is set to merge with Breeze Holdings Acquisition Corp., aiming for a Nasdaq listing by early 2025, with an estimated enterprise value of nearly $700 million. The merger will enhance YD Biopharma's capabilities in cancer diagnostics and therapeutics.
Recent Developments: YD Biopharma has secured patents and U.S. authorization for advanced detection technologies for pancreatic and breast cancer, expanding its product offerings and establishing a laboratory dedicated to early cancer detection.
Breeze Holdings Acquisition Corp. Provides Update on Trading Status and Potential Business Combination
Breeze Holdings Acquisition Corp. Trading Update: Breeze Holdings has received approval to trade on the OTCQX Best Market, with its common stock and warrants now available under the tickers "BRZH" and "BRZHW" as of August 21, 2024.
Business Combination Plans: Following the termination of a business combination with TV Ammo, Inc., Breeze intends to pursue other potential business combinations, with a deadline set by the SEC for completion by December 26, 2024.
Gateway Group Announces Preliminary Presenting Companies for Gateway Conference in San Francisco on September 4-5, 2024
Breeze Holdings Acquisition Corp. Announces Nasdaq Panel Approval for Continued Listing to Complete Initial Business Combination by May 28, 2024
Breeze Acquisition Corp. II Prices IPO at $10 per Unit
- IPO Pricing Announcement: Breeze Acquisition Corp. II has priced its initial public offering of 12,500,000 units at $10.00 per unit, with trading expected to commence on May 13, 2026, indicating strong market confidence in its future business combinations.
- Unit Composition and Trading: Each unit consists of one ordinary share and one right, with rights allowing holders to receive one-fifth of an ordinary share upon the completion of a business combination, designed to attract investors and enhance market appeal.
- Underwriters and Over-Allotment: IB Capital LLC and I-Bankers Securities, Inc. are acting as book-running managers, with underwriters granted a 45-day option to purchase up to 1,875,000 additional units, reflecting strong demand for the offering.
- Use of Proceeds and Strategic Focus: The net proceeds from the offering will be utilized to fund business combinations with companies having global operations and differentiated technologies, particularly in healthcare, biotechnology, and artificial intelligence, highlighting the company's focus on high-growth sectors.
Breeze Holdings Acquisition Corp. Shareholders Approve Business Combination with YD Biopharma Limited
Business Combination Approval: Breeze Holdings Acquisition Corp. has received stockholder approval for its business combination with YD Biopharma Limited, a Taiwan-based biopharmaceutical company, and the new entity will be named YD Bio Limited, expected to trade on Nasdaq under the ticker symbol "YDES."
Company Focus and Future Plans: YD Biopharma is dedicated to developing innovative vaccines and therapeutics for infectious diseases and aims to transform treatment options for various high unmet medical needs, with the transaction expected to close within two weeks.
Breeze Holdings Acquisition Corp. Announces Definitive Agreement to Merge with YD Biopharma Limited
Proposed Merger: YD Biopharma is set to merge with Breeze Holdings Acquisition Corp., aiming for a Nasdaq listing by early 2025, with an estimated enterprise value of nearly $700 million. The merger will enhance YD Biopharma's capabilities in cancer diagnostics and therapeutics.
Recent Developments: YD Biopharma has secured patents and U.S. authorization for advanced detection technologies for pancreatic and breast cancer, expanding its product offerings and establishing a laboratory dedicated to early cancer detection.
Breeze Holdings Acquisition Corp. Provides Update on Trading Status and Potential Business Combination
Breeze Holdings Acquisition Corp. Trading Update: Breeze Holdings has received approval to trade on the OTCQX Best Market, with its common stock and warrants now available under the tickers "BRZH" and "BRZHW" as of August 21, 2024.
Business Combination Plans: Following the termination of a business combination with TV Ammo, Inc., Breeze intends to pursue other potential business combinations, with a deadline set by the SEC for completion by December 26, 2024.
Gateway Group Announces Preliminary Presenting Companies for Gateway Conference in San Francisco on September 4-5, 2024
Breeze Holdings Acquisition Corp. Announces Nasdaq Panel Approval for Continued Listing to Complete Initial Business Combination by May 28, 2024
